



- Stock: In Stock
- Model: 183683
0% Customers recommend this product
-
5 Awesome0%
-
4 Great0%
-
3 Average0%
-
2 Bad0%
-
1 Poor0%
Reviews Over Forksiga of the tab. of p/o of 10 mg No. 30
- (0)
Total Reviews (0)
click here write review to add review for this product.
Report this review.
Description
Tablets of Forksiga are shown to adults for treatment of insufficiently controlled diabetes 2 types as addition to a diet and physical activities; as monotherapy when use of metformin is considered impossible because of intolerance of drug; in combination with other medicines for treatment of type 2 diabetes.
Structure
Active ingredient: dapagliflozin;
1 tablet, coated, contains 6.15 mg 12.30 mg to a monohydrate pro-pan-diol dapagliflozin in terms of dapagliflozin 5 mg or 10 mg;
Excipients: cellulose microcrystalline, lactose, krospovidon, silicon dioxide, magnesium stearate, opadray AI yellow.
Contraindication
Hypersensitivity to active ingredient or to any of excipients.
Route of administration
Forksiga Medicine needs to be accepted inside once a day at any time, irrespective of meal. It is necessary to swallow of tablets entirely. >
Pregnant
it is not recommended by
Feature of use
to p during the second and third trimesters of pregnancy.Drivers
With care.
OverdoseDapagliflozin did not show to
any signs of toxicity at healthy participants of a research at oral administration of single doses to 500 mg (50 times higher than the maximum recommended dose for the person). In these participants of a research it was possible to find glucose in urine during the dose-dependent span (not less than 5 days for a dose of 500 mg) without cases of dehydration, arterial hypotension of an electrolytic imbalance and also without clinically significant action on QTc interval. Frequency of development of a hypoglycemia was similar frequencies in group of use of placebo. should begin with
in case of overdose the corresponding supporting treatment, is defined by a clinical condition of the patient. A conclusion of a dapagliflozin by means of a hemodialysis was not studied.
Side effects
from a metabolism and food: hypoglycemia.
Interaction
Use of a dapagliflozin can increase diuretic effect of thiazide and loopback diuretics and also can increase risk of developing dehydration and arterial hypotension.
Insulin and means strengthening insulin secretion such as sulphonylurea drugs, cause development of a hypoglycemia. Thus, for reduction of risk of development of a hypoglycemia at use in a combination with dapaglifloziny there can be reasonable a use of lower doses of insulin or the means strengthening insulin secretion.
Storage conditionsto Store
out of children's reach at a temperature up to 25 °C.
Expiration date - 3 years.
Specifications
Characteristics | |
Active ingredients | Dapagliflozin |
Amount of active ingredient | 10 mg |
Applicant | AstraZeneca |
Code of automatic telephone exchange | A10BK01 Dapagliflozin |
Interaction with food | It doesn't matter |
Light sensitivity | Not sensitive |
Market status | Original |
Origin | Chemical |
Prescription status | According to the prescription |
Primary packing | blister |
Producer | ASTER OF ZENEKA YUK LIMITED |
Quantity in packing | 30 tablets (3 blisters on 10 pieces) |
Release form | tablets for internal use |
Route of administration | Oral |
Sign | Import |
Storage temperature | from 5 °C to 25 °C |
Trade name | Forksiga |